Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
February 2, 2024 7:42 AM ESTShares of Bristol-Myers Squibb (NYSE: BMY) advanced 2.5% in the market pre-open Friday after the pharmaceutical company unveiled better-than-expected earnings and revenue for the fiscal fourth quarter.
Notably, Bristol reported Q4 earnings per share (EPS) of $1.70, ahead of Wall Streets consensus of $1.60. Revenue stood at $11.48 billion in the... More
